ArticleBreast care (Basel, Switzerland)
Targeted Therapy: Can It Substitute for Chemotherapy?
Article in Breast care (Basel, Switzerland). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 citations in OpenAlex.
- Multimarker Analysis of Circulating Tumor Cells in Peripheral Blood of Metastatic Breast Cancer Patients: A Step Forward in Personalized Medicine.Breast care (Basel, Switzerland) · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Every oncologist has a dream - doing more with less toxicity. Targeted therapies seem to be the key for an oncologist's dreams by defining subgroups of those patients who benefit more from a specific treatment and those who do not. For a few years now, targeted therapies have played a major role in the treatment of primary as well as metastatic breast cancer. In this article, we describe targeted therapies that already play an important role in clinical decisions in the treatment of metastatic as well as primary breast cancer. The humanised monoclonal antibody trastuzumab is a very effective agent in primary and metastatic breast cancer, but only for those patients whose tumours are overexpressing HER2/neu. Bevacizumab is an antibody directed against vascular epidermal growth factor ligand A which plays a role in angiogenesis. Up to now there is no predictive factor known for this treatment. Furthermore, we would like to give an impression of new agents and strategies under investigation like tyrosine kinase inhibitors and other small molecules.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.